ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.

Quote:

Search for Ticker

Free Membership

Search:

WCRX: Warner Chilcott Plc Ord Cl A Ire - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

WARNER CHILCOTT PLC ORD CL A IRE (NASD)
WCRX	24.22	0.42	(1.76%)	Vol. 1,711,165	16:00 ET

Warner Chilcott PLC, formerly Warner Chilcott Limited, is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceutical market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. The company has established strong franchises in women's healthcare and dermatology through its marketing techniques and specialty sales forces. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. The company is headquartered in Rockaway, New Jersey.

General Information

WARNER CHIL PLC

100 Enterprise Drive Rockaway, NJ 07866 Phone: 973-442-3200 Fax: 973-442-3283 Web: www.warnerchilcott.com Email: ir@wcrx.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/19/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	23.80
52 Week High	24.45
52 Week Low	9.24
Beta	0.81
20 Day Moving Average	1,807,854.38
Target Price Consensus	26.19

% Price Change
4 Week	8.58
12 Week	22.62
YTD	64.14

% Price Change Relative to S&P 500
4 Week	4.43
12 Week	10.68
YTD	31.16

Share Information
Shares Outstanding (millions)	251.32
Market Capitalization (millions)	5,981.30
Short Ratio	4.64
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.50
Current Year EPS Consensus Estimate	1.75
Estimated Long-Term EPS Growth Rate	10.70
Next EPS Report Date	02/19/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.29
30 Days Ago	1.75
60 Days Ago	1.75
90 Days Ago	1.89

Fundamental Ratios

P/E
Current FY Estimate:	13.61
Trailing 12 Months:	14.60
PEG Ratio	1.28

EPS Growth
vs. Previous Year	5.13%
vs. Previous Quarter	-6.82%

Sales Growth
vs. Previous Year	8.99%
vs. Previous Quarter:	0.79%

Price Ratios
Price/Book	3.16
Price/Cash Flow	9.80
Price / Sales	6.03

ROE
09/30/09	26.94
06/30/09	28.48
03/31/09	26.90

ROA
09/30/09	15.74
06/30/09	15.44
03/31/09	14.20

Current Ratio
09/30/09	2.86
06/30/09	1.96
03/31/09	1.49

Quick Ratio
09/30/09	2.67
06/30/09	1.64
03/31/09	1.12

Operating Margin
09/30/09	41.43
06/30/09	41.63
03/31/09	39.74

Net Margin
09/30/09	45.81
06/30/09	5.27
03/31/09	3.17

Pre-Tax Margin
09/30/09	45.81
06/30/09	5.27
03/31/09	3.17

Book Value
09/30/09	7.53
06/30/09	5.81
03/31/09	5.56

Inventory Turnover
09/30/09	3.10
06/30/09	3.35
03/31/09	3.44

Debt-to-Equity
09/30/09	0.20
06/30/09	0.59
03/31/09	0.61

Debt to Capital
09/30/09	16.71
06/30/09	36.92
03/31/09	37.99


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research